Review



pegfr y845  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pegfr y845
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr Y845, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 114 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/bio_rxiv__64898__2025__12__19__695123-33-21-24?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 114 article reviews
    pegfr y845 - by Bioz Stars, 2026-08
    93/100 stars

    Images

    1) Product Images from "EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide"

    Article Title: EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide

    Journal: bioRxiv

    doi: 10.64898/2025.12.19.695123

    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Figure Legend Snippet: A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).

    Techniques Used: Staining, Fluorescence, Flow Cytometry, Phospho-proteomics, Cell Counting



    Similar Products

    pegfr y845  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc pegfr y845
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr Y845, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/bio_rxiv__64898__2025__12__19__695123-33-21-24?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 1 article reviews
    pegfr y845 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    anti pegfr  (R&D Systems)
    93
    R&D Systems anti pegfr
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Anti Pegfr, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pm40157366-38-117-118?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti pegfr - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    pegfr (y845)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc pegfr (y845)
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr (Y845), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pmc11166458__joces___137___262116___s1-46-67-70?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    pegfr (y845) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    antibodies directed against arv7, egfr/pegfr (y845), erk/perk (t202/y204)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies directed against arv7, egfr/pegfr (y845), erk/perk (t202/y204)
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Antibodies Directed Against Arv7, Egfr/Pegfr (Y845), Erk/Perk (T202/Y204), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pm36343786-134-6-11?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    antibodies directed against arv7, egfr/pegfr (y845), erk/perk (t202/y204) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    pegfr y845  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology pegfr y845
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr Y845, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pm33340661-50-4-19?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    pegfr y845 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    pegfr y845  (R&D Systems)
    91
    R&D Systems pegfr y845
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr Y845, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pmc08619104-31-14-17?v=R%26D+Systems
    Average 91 stars, based on 1 article reviews
    pegfr y845 - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    anti pegfr y845  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc anti pegfr y845
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies <t>(pEGFR</t> <t>Y845</t> or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Anti Pegfr Y845, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y845/pm29669739-174-8-11?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 1 article reviews
    anti pegfr y845 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).

    Journal: bioRxiv

    Article Title: EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide

    doi: 10.64898/2025.12.19.695123

    Figure Lengend Snippet: A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).

    Article Snippet: TOM20 #612278, BD (Le Pont de Claix, France); TFAM #8076, Cell Signaling Technology (Danvers, MA, USA); EGFR #4267, Cell Signaling Technology; pEGFR Y845 #6963, Cell Signaling Technology; pEGFR Y1068 #3777, Cell Signaling Technology; TBK1 #3504, Cell Signaling Technology; pTBK1 #5483, Cell Signaling Technology; pSrc #sc-81521, Santa Cruz Biotechnology (Dallas, TX, France); VDAC #ab14734 Abcam, (Cambridge, UK); IP3R #sc-28614, Santa Cruz Biotechnology; LC3 #83506, Cell Signaling Technology or #L7543, Sigma Aldrich.

    Techniques: Staining, Fluorescence, Flow Cytometry, Phospho-proteomics, Cell Counting